LightNews LightNews
atmpcgt.bsky.social
@atmpcgt.bsky.social
23 followers 97 following 5 posts
Posts Replies Media Videos
Pinned
atmpcgt.bsky.social
atmpcgt.bsky.social @atmpcgt.bsky.social · Nov 29
Stem Cells and Regenerative Medicine business

flipboard.com/@it22/stem-c...
Reposted
natbiotech.nature.com
The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial www.nature.com/articles/s41...
rdcu.be/euaoK
Individualized mRNA cancer vaccines make strides - Nature Biotechnology
The first cancer vaccines matched to a person’s unique tumor neoantigens are forging ahead, with expectations running high as the field awaits results from the first pivotal trial.
www.nature.com
June 30, 2025 at 6:48 PM
atmpcgt.bsky.social
SPLICER shows promise in Alzheimer's and other diseases

flip.it/dcse3m
SPLICER shows promise in Alzheimer's and other diseases
A new gene editing tool that helps cellular machinery skip parts of genes responsible for diseases has been applied to reduce the formation of amyloid-beta plaque precursors in a mouse model of Alzhei...
flip.it
December 24, 2024 at 7:56 AM
atmpcgt.bsky.social
CDD = Clinical Drug Development = collection of articles & news.

flipboard.com/@it22/cdd-b8...
CDD | @IT22 | Flipboard
clinical drug development
flipboard.com
December 15, 2024 at 6:08 PM
atmpcgt.bsky.social
New data underline cancer risk of Bluebird therapy for brain disease.

#genetherapy
#Skysona

flip.it/Uv6eRF
New data underline cancer risk of Bluebird therapy for brain disease
Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.
flip.it
December 15, 2024 at 5:38 PM
atmpcgt.bsky.social
#Genetherapy uptake in sickle cell stays slow, despite patient interest...

flip.it/4L-fgj
Gene therapy uptake in sickle cell stays slow, despite patient interest
A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of Casgevy and Lyfgenia during their first year on market.
flip.it
December 9, 2024 at 5:13 PM
atmpcgt.bsky.social
Stem Cells and Regenerative Medicine business

flipboard.com/@it22/stem-c...
November 29, 2024 at 9:12 AM